This week's roundup includes CEO appointments by various companies including Mustang Bio, GammaDelta and Modus Therapeutics and other high-level appointments by Bayer, Renova, Metrion and Poxel.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.

Big Pharma has provided its executives with unrivaled stability, opportunity, and financial rewards, but swelling numbers are fleeing corporate offices for tiny biotechs. A blip in good times for biotech or a sea change for the industry?

Big Pharma has provided its executives with unrivaled stability, opportunity, and financial rewards, but swelling numbers are fleeing corporate offices for tiny biotechs. A blip in good times for biotech or a sea change for the industry?